Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA Commitments Won’t Be Met If Congress Nixes White Oak Funding

Executive Summary

President Obama’s FY 2014 budget proposal argues that Congressional failure to provide FDA with additional funding for its White Oak consolidation efforts could force GDUFA hiring to stall, jeopardizing the agency’s ability to meet the user fee commitments negotiated with industry.

You may also be interested in...



FDA’s Budget Proposal: It’s The User Fees’ Agency Now

User fees, not appropriations, will make up the bulk of FDA’s human drug spending if President Obama’s FY 2014 budget comes to pass, a trend fueled by new user fee programs and cuts to taxpayer funding.

GDUFA Self-Identification Woes Can’t Deflate Industry, FDA Enthusiasm

As the grace period nears its close, industry officials say they expected problems getting generic drug manufacturing facilities to self-identify under the new user fee requirement; meanwhile, FDA expects to hire nearly three times the staff in the Office of Generic Drugs to meet GDUFA commitments.

CBER Strategic Plan Showcases New Lab Complex, Research Projects For Cancer, Rare Diseases

Center for Biologics Evaluation and Research describes the Life Sciences-Biodefense Laboratory scheduled for completion in December 2013 and its plans to facilitate development of safe and effective products.

Related Content

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel